文献速递消化道肿瘤放疗放疗物理与技术

立体定向体部放疗治疗胰腺癌:最大化肿瘤控制与限制并发症

Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-12-24

该HyTEC综述通过PubMed检索汇总胰腺癌SBRT文献,用α/β=10 Gy的线性二次模型和逻辑肿瘤控制概率模型比较不同分割方案的疗效。汇总模型提示1年局部控制率在3次等效剂量25-36 Gy范围呈剂量反应,3次等效剂量28 Gy以上且切缘阴性切除时1年局部控制率超过90%。

要点

  • 3次等效剂量25-36 Gy范围显示剂量反应,低于24 Gy/3次时1年局部控制率降至70%以下。
  • 33 Gy/5次方案对应3次等效剂量28.2 Gy,汇总模型1年未手术局部控制率为77%。
  • 3次等效剂量28 Gy以上且切缘阴性切除时,1年局部控制率超过90%。

核心结论

  • 常用SBRT剂量分割方案的汇总肿瘤控制概率分析提示存在剂量反应。
  • 鉴于本综述的挑战与局限性,这些发现应谨慎看待,仍需更多数据理解剂量或分割反应。

研究设计与样本

  • HyTEC综述,通过PubMed检索已发表的胰腺癌大分割SBRT(通常1-5次)文献。
  • 使用α/β=10 Gy的线性二次模型处理分割差异,并用最大似然参数拟合生成逻辑肿瘤控制概率模型。

主要发现

  • 转换为3次等效剂量后,汇总数据与模型提示未手术1年局部控制率在3次等效剂量30至36 Gy时约为79%至86%。
  • 3次等效剂量25至36 Gy范围显示剂量反应,低于24 Gy/3次时1年局部控制率降至70%以下。
  • 33 Gy/5次方案(Alliance A021501)对应3次等效剂量28.2 Gy,HyTEC汇总模型未手术1年局部控制率为77%。
  • 3次等效剂量28 Gy以上且切缘阴性切除时,1年局部控制率超过90%。

关键数值与推荐

  • 3次等效剂量30至36 Gy对应未手术1年局部控制率约79%至86%。
  • 3次等效剂量低于24 Gy对应1年局部控制率低于70%。
  • 33 Gy/5次对应3次等效剂量28.2 Gy,汇总模型未手术1年局部控制率77%。
  • 3次等效剂量28 Gy以上且切缘阴性切除时1年局部控制率超过90%。

临床怎么用

  • 可参考3次等效剂量与1年局部控制率的剂量反应关系评估SBRT分割方案。
  • 对切缘阴性切除患者,3次等效剂量28 Gy以上与超过90%的1年局部控制率相关。
  • 低于3次等效剂量24 Gy时1年局部控制率低于70%,应谨慎选择该剂量范围。

局限性

  • 本综述存在挑战与局限性,发现应谨慎看待。
  • 仍需额外数据以更好理解胰腺癌SBRT的剂量或分割反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiation therapy (SBRT) and stereotactic ablative body radiation therapy is being increasingly used for pancreatic cancer (PCa), particularly in patients with locally advanced and borderline resectable disease. A wide variety of dose fractionation schemes have been reported in the literature. This HyTEC review uses tumor control probability models to evaluate the comparative effectiveness of the various SBRT treatment regimens used in the treatment of patients with localized PCa. METHODS AND MATERIALS: A PubMed search was performed to review the published literature on the use of hypofractionated SBRT (usually in 1-5 fractions) for PCa in various clinical scenarios (eg, preoperative [neoadjuvant], borderline resectable, and locally advanced PCa). The linear quadratic model with α/β= 10 Gy was used to address differences in fractionation. Logistic tumor control probability models were generated using maximum likelihood parameter fitting. RESULTS: After converting to 3-fraction equivalent doses, the pooled reported data and associated models suggests that 1-year local control (LC) without surgery is ≈79% to 86% after the equivalent of 30 to 36 Gy in 3 fractions, showing a dose response in the range of 25 to 36 Gy, and decreasing to less than 70% 1-year LC at doses below 24 Gy in 3 fractions. The 33 Gy in 5 fraction regimen (Alliance A021501) corresponds to 28.2 Gy in 3 fractions, for which the HyTEC pooled model had 77% 1-year LC without surgery. Above an equivalent dose of 28 Gy in 3 fractions, with margin-negative resection the 1-year LC exceeded 90%. CONCLUSIONS: Pooled analyses of reported tumor control probabilities for commonly used SBRT dose-fractionation schedules for PCa suggests a dose response. These findings should be viewed with caution given the challenges and limitations of this review. Additional data are needed to better understand the dose or fractionation-response of SBRT for PCa.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Mahadevan A, Moningi S, Grimm J, et al. Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 33358561. doi:10.1016/j.ijrobp.2020.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。